CRO Communiqué
Keeping you informed about CRO progress
August 2014

Top Enrolling Physicians for July 2014

<table>
<thead>
<tr>
<th>Physician</th>
<th>Patient Registrations</th>
<th>Treatment Credits</th>
<th>Control Credits</th>
<th>Total Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Carlson (Mercy Spfld)</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dr. Gillette (Cox)</td>
<td>1</td>
<td>0</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Dr. Hans0n (Mercy St. Louis)</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Dr. Miller (Freeman)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Dr. Nair (Mercy Spfld)</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Dr. Shunyakov (Central Care)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Dr. Rogers (Mercy St. Louis)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>7</td>
<td>6</td>
<td>2.6</td>
<td>8.6</td>
</tr>
</tbody>
</table>

Enrollments have continued to be slow this month. CRO earned 6 treatment and 2.6 control credits in July. We are eager for new studies to be activated.

NCORP Program
SUPER news! We have received funding for our NCORP grant! Dr. Carlson has been notified by Senator Blunt’s office that a $5 million grant ($1,040,000/year over five years) has been approved through the National Cancer Institute. Efforts are being made to get media coverage for this great event. Only 40 organizations received this award across the U.S., so we’re hoping to make a splash with the news. It is an honor to be selected for the NCORP award. Many transitional pieces are in process as we move to the new program. Information on the NCORP program can be found at http://ncorp.cancer.gov.

CRO Steering Committee Meeting
Mark your calendars for 6pm on Tuesday, August 19th for CRO’s next Steering committee meeting. The meeting begins at 6pm at Metropolitan Grill. Heather Hermann, MS CGC will be our speaker. Ms. Hermann is a certified genetic counselor at the University of Pittsburgh. She has worked with Myriad’s Medical Specialist Team which provide field and phone based support to physicians. Please let Debbie know at 269-4520 if you plan to attend by Friday, August 15th.

CoxHealth and Mercy Springfield to Participate in COC Pilot
CRO’s sponsoring Institutions, CoxHealth and Mercy Springfield will be participating in a Commission on Cancer Special Study. The study will involve analyzing data from the NCDB to determine surveillance patterns for colorectal, breast and lung cancers. It will be funded by 3 research funding contracts from the Patient Center Outcomes Research Institute (PCORI). The study goal of this work is to better understand which patients are currently being followed with surveillance imaging and whether or not this is influencing outcomes. The Commission on Cancer has deemed this Special Study a priority area.

NCI Administrative Supplement for Blood Samples
CRO is submitting an application to receive additional funding for submitting 100 blood samples to NCI to assist in the development of a tissue repository. A maximum of $50,000 will be awarded to ten sites. The application is to be submitted on or before August 8, 2014.

Study Profile
Our study profile is Alliance A221301 ‘Olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC); A randomized, double-blind, placebo-controlled trial’ This randomized phase III trial studies antiemetic (prevents or reduces nausea and vomiting) therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by blocking brain receptors that appear to be involved in nausea and vomiting. Giving antiemetic therapy with olanzapine may help to reduce or prevent nausea and vomiting in patients treated with highly emetogenic chemotherapy. This study is in pre-activation but should be activated any day.
New Studies Approved in July, 2014 Through Cox and Mercy’s IRB

**Alliance A091305** A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination With Paclitaxel Versus Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

**ECOG-ACRIN E2511** Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

---

New Studies Approved and Opened in July with the CIRB

None

---

Closed Studies in July, 2014

**GOG-0229L** A Phase II Trial of AMG 386 (IND #111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium

**GOG-0231D** A Phase II Evaluation of MLN8237 (IND#113149 NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

**GOG-0273** Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

**RTOG 1016** Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer